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htticense.Abstract Optimization of fermentation process conditions using a gene ampliﬁed variant of Amy-
colatopsis mediterranei (NCH) was carried out. The use of aeration level 1.5 vvm increased the yield
by 16.6% (from 13.81 to 16.1 g/l) upon controlling the temperature at 28 C. Adjustment of the aer-
ation level at 1.5 vvm for 3 days then controlling the dissolved oxygen (DO) at 30% saturation fur-
ther increased the yield to 17.8 g/l. The optimum pH was 6.5 for 3 days then 7 thereafter when a
production yield of 16.1 g/l was recorded using an aeration rate of 1.5 vvm. Controlling the pH
at constant value (6.5 or 7) all through the fermentation process decreased the yield by 5–21%. Con-
trolling the temperature at 30 C for 3 days then 28 C thereafter slightly increased the yield by 5%
upon using an aeration rate of 1 vvm while it decreased upon using an aeration rate of 1.5 vvm.
Integration of the most optimum conditions increased the production yield by 22% from 13.81
to 17.8 g/l.
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Rifamycins, mainly rifamycin B, belong to the ansamycin anti-
biotic family with pronounced anti-mycobacterial activity.1,2
They are used in the chemotherapeutic treatment of tuberculo-
sis, leprosy and AIDS-related mycobacterial infections.3 These
antibiotics regained importance due to their use in the treat-
ment of AIDS associated tuberculosis.1,4 With the increasing
demand of this antibiotic in terms of its utility spectrum in
the current AIDS outbreak the world forced the scientiﬁc com-
munity to look for a novel antibiotic environment or increaseaculty of Pharmacy, Cairo University.
3.02.002
44 H.F. El-Sedawy et al.the productivity with the existing microbial system by modify-
ing the cultivation procedures.
Usually, the productivity of the desired product is high in
ﬂask scale, and will be gradually reduced as the scale is en-
larged because of the complexity of the fermentation pro-
cesses.5 Accordingly, results obtained in the shake ﬂasks
should be taken only as preliminary indicators for the condi-
tions necessary for successful industrial production through
pre-designed scaling-up studies and must be veriﬁed in studies
carried out in a bench scale fermentor. The method for scaling-
up a fermentation system is usually based on empirical criteria
such as pH, temperature, constant power input per unit vol-
ume, a constant mass transfer coefﬁcient, constant mixing time
and a constant impeller tip velocity.5,6
Agitation power per unit volume is among the most fre-
quently used parameters for scale-up. Where sensor technolo-
gies developed for dissolved oxygen (DO) concentration, the
scale-up method to maintain DO at a constant level became
popular.5,7 Culturing ﬁlamentous microorganisms such as fun-
gi or actinomycetes in a large fermentor could subject cells to
damage by the exerted shear stress,8 and consequently the
product yield is reduced. Hence, a compromise shall be at-
tempted to achieve a sufﬁcient level of DO with minimum pos-
sible shear stress.9
Indeed, each organism has its optimum pH where the
growth of a selected microbial strain and its cellular metabo-
lism occur in optimum levels compared to other conditions.5
Rifamycin fermentation shows an interesting pH pattern
where the initial neutral pH increases continuously to an alka-
line pH region in the initial growth phase, followed by a de-
crease to acidic pH at the beginning of the production of
rifamycin. The pH of the medium affected both cell growth
and rifamycin B production. Several authors reported the ef-
fect of pH on the cell growth and rifamycin B production at
different pH values.10
The inﬂuence of incubation temperature on antibiotic pro-
duction was studied by several authors.11,12 These studies
showed that lowering the temperature decreases the rate of
glucose consumption. It has also often been observed that a
lower rate of carbon metabolism in the initial growth phase re-
sults in higher antibiotic production.12,13 For instance, Maha-
laxmi et al.,1 reported that maximum growth and antibiotic
production were noticed at 28 C and variation of this temper-
ature resulted in the reduction of both biomass and produc-
tion. Hence, it could be concluded that the optimal
temperature for rifamycin B production is strain speciﬁc.12,13
In this prospective, the present study aimed to improve and
optimize the fermentation process conditions to achieve a bet-
ter yield of rifamycin B. The signiﬁcant conditions that govern
the fermentation process, such as aeration, dissolved oxygen,
pH as well as the temperature were studied. Final integration
of the optimized conditions was attempted to investigate the
maximum possible yield.2. Materials and Methods
2.1. Bacterial strains
The ampliﬁed variant NCH of Amycolatopsis mediterranei–
RCP 1001, previously obtained by El-Tayeb et al.14 was main-
tained on Q/2 agar slants and stored at 4 C to be used within27 days. The strain was propagated on Bennett’s agar. For
long-term storage, the surface growth on Q/2 agar slants was
harvested in 10% skimmed milk and lyophilized.
2.2. Chemicals
Chemicals used throughout this work were of laboratory re-
agent grade, unless otherwise indicated. Glucose monohydrate,
sucrose, NH4NO3, NaNO2 were the products of ADWIC,
Egypt. Sodium diethyl barbiturate (SDB) was the product of
Grindstedvaerket A/S, Denmark. Potassium sodium tartarate
tetrahydrate, 3,5_dinitrosalicylic acid, CaCO3, MgSO4.7H2O,
KH2PO4, (NH4)2SO4, NaOH and HCl were the products of
E. Merck, Darmstadt, Germany. Glacial acetic acid was the
product of Aldrich Ltd, England.
2.3. Media
Yeast extract, malt extract, beef extract, tryptone, soytone,
skimmed milk and bacto agar were the products of Difco Lab-
oratories, Detroit, U.S.A. Oat ﬂakes and sunﬂower oil were
obtained from commercial suppliers. Glucose syrup was ob-
tained from the Egyptian Co. for Production of Starch and
Glucose, Cairo.
Media used for propagation, selection and maintenance as
well as the vegetative medium V2 were those previously re-
ported by El-Tayeb et al.15 The modiﬁed fermentation medium
F2m3 was prepared and used according to El-Tayeb et al.13
2.4. Inoculum preparation and analytical regime
The methods used for maintenance, propagation, selection
and preparation of inoculums as well as the determination
of the remaining reducing sugars concentration, biomass
and assay of rifamycin B were previously reported by El-
Tayeb et al.13,15
2.5. Production of rifamycin B in the fermentor
The production of rifamycin B was carried out in a 6.6 liter
laboratory glass fermentor (Bioﬂo 3000 Benchtop fermentor,
New Brunswick Scientiﬁc Co., NJ, USA) as previously de-
scribed by El-Tayeb et al.13 The inoculum was prepared
according to El-Tayeb et al.15 and was added (5% v/v) to 2.5
liters of F2m3 medium to which 5% glucose syrup was added
at day 4. Unless otherwise indicated, agitation was kept at
500 rpm by using 2 six bladed Rushton impellers separated
by 9.5 cm with the lower impeller 2.5 cm above the agitator
tip. Aeration using a multioriﬁce ring sparger was controlled
by a pressure regulator and monitored by a ﬂowmeter.
The% of dissolved oxygen (DO) was monitored and/or con-
trolled through the fermentor control unit using the airﬂow
and the agitation speed simultaneously.
The impact of commonly known key parameters was stud-
ied through different sets of experiments (Table 1). Unless
otherwise indicated, the temperature was adjusted at 28 C,
the pH was automatically controlled at 6.5 for 3 days then 7
thereafter, an agitation rate at 500 rpm and aeration at
1 vvm. Samples of 25 ml were periodically withdrawn every
24 h for analysis of rifamycin B concentration, remaining
reducing sugars concentration and dry cell weight.
Table 1 Optimization of rifamycin B production by NCH strain using F2m3 medium in batch mode in the fermentor.
Variable factors Fermentation conditionsa
Agitationb (rpm) Aeration (vvm) pH Dissolved oxygen (DO) Temperature (C) Rifamycin B conc. (g/l) % Change
(Control) 500 1 C UC 28 13.8
Aerationc
1.5 500 Vf C UC 28 16.1 (+) 16.6
Dissolved oxygen regimens (DO)
1 vvm for 3 days then controlled DO at 30% (control) Vf Vf C Vf 28 16.1 (+) 16.6
1 vvm for 2 days then controlled DO at 30% C 28 12.7 () 8.0
1 vvm for 2 day then controlled DO at 60% C 28 13.8 0
1.5 vvm for 3 days then controlled DO at 30%. C 28 17.8 (+) 29.0
DO control at 60% from zero time C 28 15.3 (+) 10.8
pHd
6.5 500 1 Vf UC 28 13.1 () 5.0
7.0 500 1 UC 28 10.8 () 21.0
6.5 for 3 days then 7.5 thereafter 500 1 UC 28 13.5 () 2.0
6.5 for 3 days then 7 thereafter (control) 500 1 UC 28 13.8 . . .. . ..
6.5 for 3 days then 7 thereafter 500 1.5 UC 28 16.1 (+) 16.6
Temperaturee
28 C for 18 h then 24 thereafter 500 1 C UC Vf 7.5 () 45
28 C for 18 h then 26 thereafter 500 1 C UC 13.2 () 4.5
26 C 500 1 C UC 12.7 () 8
28 C (control) 500 1 C UC 13.8 . . .. . ..
30 C 500 1 C UC 11.5 () 16.5
30 C for 3 days then 28 C thereafter 500 1 C UC 14.5 (+) 5
30 C for 3 days then 28 C thereafter 500 1.5 C CDOg 15.5 (+) 12.5
F2m3; incubation temperature, 28 C; pH 6.5 for 3 days then 7 thereafter; inoculum size, 5% and the incubation period, 192 h unless otherwise indicated.
(C) Control pH at 6.5 for 3 days then 7 thereafter. (UC) Uncontrolled.
a The following conditions were kept constant in all investigations unless otherwise prescribed: the fermentation medium.
b Agitation was kept at 500 rpm except in DO control regimes.
c Without DO control.
d All the tested pH regimes were carried out without DO control.
e All the tested temperature regimes were carried out without DO control.
f Variable.
g The DO was controlled at 30% of saturation after 3 days.
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Figure 1 Effect of aeration rate 1.5 vvm on (A) rifamycin B
concentration, dry cell weight and (B) remaining reducing sugars’
concentration and dissolved oxygen concentration using NCH
strain in a 6.6 l fermentor under the following conditions:
aeration, 1.5 vvm; agitation, 500 rpm; inoculum size, 5%; working
volume, 2.5 l; medium used, F2m3; 5% glucose syrup was added
at day 4; pH, 6.5 for 3 days then 7 thereafter; temperature, 28 C.
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Figure 2 Effect of different DO control regimes on (A) rifamycin
B production and (B) dry cell weight using an NCH strain in a
6.6 l fermentor under the following conditions: aeration, 1 or
1.5 vvm; agitation, 500 rpm; inoculum size, 5%; working volume,
2.5 l; medium used, F2m3; 5% glucose syrup was added at day 4;
pH, 6.5 for 3 days then 7 thereafter; temperature, 28 C.
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Figure 3 Effect of different pH control regimes on rifamycin B
production and dry cell weight using an NCH strain in a 6.6 l
fermentor under the following conditions: aeration, 1 vvm; agita-
tion, 500 rpm; inoculum size, 5%; working volume, 2.5 l; medium
used, F2m3; 5% glucose syrup was added at day 4; temperature,
28 C.
46 H.F. El-Sedawy et al.3. Results
Application of 1.5 vvm aeration rate increased the yield of rif-
amycin B to 16.1 g/l (16.6%) compared to 13.8 g/l (Fig. 1A).
This yield was accompanied by a higher biomass and higher
substrate consumption (Fig. 1). Moreover, the DO reached
zero at day 7 upon the use of 1.5 vvm compared to zero value
at day 5 in case of the use of an aeration rate of 1 vvm.
(Fig. 1B).
Different regimes for controlling DO were tested (Table 1
and Fig. 2). The best regime was the use of 1.5 vvm for 3 days,
then controlling DO at 30% of saturation to the end of the
process, where the yield increased by 10.5% (from 16.1 to
17.8 g/l). This was followed by the application of 1.5 vvm then
by controlling DO at 60% saturation from zero time (Fig. 2A).
The other regimes resulted in comparable production as con-
trol (Table 1 and Fig. 2A). The recorded dry cell weight was
higher than the control in all the tested regimes (Fig. 2B), while
the remaining reducing sugars concentration showed almost
the same pattern as the control (data not shown).
In general, all 4 tested regimes for controlling pH at an
aeration rate of 1 vvm had either no or negative impact of
Scaling up for the industrial production of rifamycin B; optimization of the process conditions in bench-scale fermentor 47rifamycin B production compared to the control (Table 1). The
lowest production yield was recorded when the pH was
adjusted at 7 (Fig. 3). Other attempted regimens resulted in a
production yield of almost the same order of magnitude and
dry cell weight especially at the end of the production
(Fig. 3). The remaining reducing sugars showed comparable
pattern as control (data not shown).
The highest yield and dry cell weight were recorded upon
adjusting the temperature at 30 C for 3 days then 28 C there-
after at 1 vvm aeration rate (Fig. 4). The lowest yield and dry
cell weight were recorded when the temperature was adjusted
at 28 C for 18 h. then 24 C thereafter (Fig. 4). The other re-
gimes decreased the yield and the recorded the dry cell weight
(Fig. 4B). The remaining reducing sugars’ concentration was
comparable to the control except for using 30 C for 3 days
then 28 C thereafter (Fig. 4C).0
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Figure 4 Effect of different temperature control regimes on (A)
rifamycin B concentration, (B), dry cell weight and (C) remaining
reducing sugars concentration using an NCH strain in 6.6 l
fermentor under the following conditions: aeration, 1 vvm; agita-
tion, 500 rpm; inoculum size, 5%; working volume, 2.5 l; medium
used, F2m3; 5% glucose syrup was added at day 4; pH, 6.5 for
3 days then 7 thereafter.The optimum conditions obtained from previous sets of
experiments suggested that a road forward for the estabilish-
ment of an optimized set of conditions. Integration of all con-
ditions which lead to the highest yield (aeration rate of 1.5 vvm
for 3 days, and controlling the DO at 30% of saturation to the
end of the process, controlling the pH at 6.5 for 3 days then at
7 thereafter, controlling the temperature at 30 C for 3 days
then 28 C thereafter) was tested. This combination decreased
the yield at day 8 from 16.1 to 15.5 g/l compared to the control
(aeration, 1.5 vvm; agitation, 500 rpm; temperature, 28 C and
pH control at 6.5 then 7 thereafter) with the reducing sugars
reaching zero at day 6 (Fig. 5).
4. Discussion
Optimization of antibiotic production necessitates the studying
of different physical and physiological factors affecting its pro-
duction; taking into concern that the optimal fermentation
conditions are usually strain speciﬁc.12,13 The use of an aera-
tion rate of 1.5 vvm increased the production yield by almost
17%. A characteristic of A. mediterranei fermentation is the
very high oxygen requirement in a deﬁnite period of the
growth–production cycle.16,17 The time at which this occurs
varies with the strain and the medium composition, but it al-
ways coincides with the phase in which glucose is rapidly
metabolized. If this oxygen demand is not met by an adequate
oxygen supply through aeration, very low ﬁnal yields of rifa-
mycin B are obtained.16 Although previously, El-Tayeb
et al.13 studied the effect of different aeration levels on rifamy-
cin B production and the results showed that the maximum rif-
amycin B production was obtained upon using 1 vvm, in the
present study the highest yield was recorded at a 1.5 vvm aer-
ation rate.
Controlling the dissolved oxygen (DO) at different regimes
resulted in an increase in the production yield with the highest
yield (10.5%) obtained by the use of 1.5 vvm for 3 days then
DO control at 30% of saturation thereafter. These results were
in accordance with those reported by El-Tayeb et al.13 where
the yield increased by 8% upon using 1 vvm for 3 days then
controlling DO at 30% thereafter. In this respect, Jin et al.5 re-
ported that rifamycin B fermentation was dependent on a high
amount of dissolved oxygen (DO), and that the DO must be0
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Figure 5 Effect of integration of optimum conditions in batch
mode on rifamycin B production (P) and remaining reducing
sugars concentration (S) by NCH strain using F2m3 medium in a
6.6 l laboratory fermentor.
48 H.F. El-Sedawy et al.kept above 25% of the saturation to meet the oxygen require-
ment for mycelia growth and rifamycin B production.
A. mediterranei has a characteristic pH behavior pattern.
Thus controlling the pH during the fermentation may be a
good way to improve rifamycin B production. Thus, El-Tayeb
et al.13 reported a characteristic pH behavior pattern of A.
mediterranei and recommended a pH strategy of 6.5 at the
trophophase (day 1–3) and 7.0 at the idiophase (day 4–8). In
the present study all the tested regimes did not increase the
yield of rifamycin B. In addition the results showed reduction
in the recorded biomass. These results were in agreement with
El-Tayeb et al.,13 who reported that the optimum pH for rifa-
mycin B production was the use of pH 6.5 at the trophophase
and pH 7.0 at the idiophase.
The optimal temperature reported for rifamycin B fermenta-
tion was 28 C.10 Data obtained by Krishna et al.10 suggested
that the fermentation carried out at 26–30 C gave the maxi-
mum yield of rifamycin and any deviation from the optimum
temperature resulted in growth retardation and decreased the
yield of antibiotic. The results of the present study showed a
slight increase in production upon using 30 C for 3 days then
28 C thereafter. Although Sensi and Thiemann18 have re-
ported that shifting the temperature from 28 C to 24 C after
18 h of fermentation increased the yield of rifamycin B produc-
tion, in the present study, a marked decrease was observed in
productivity, biomass and glucose consumption associated
with the use of 28 C for 18 h then 24 C thereafter. However,
this could be due to the difference in the strain used. Although
the use of 30 C throughout the fermentation time decreased
productivity and biomass, glucose consumption was much fas-
ter than all the tested temperature regimes. Indeed, lowering
the temperature decreases the rate of glucose consumption.
The lower the rate of carbon metabolism in the initial growth
phase the higher the antibiotic production.12,16
Integration of the most optimum conditions previously
mentioned above (1.5 vvm for 3 days then DO control at
30% thereafter, pH control at 6.5 for 3 days then 7 thereafter,
temperature control at 30 C for 3 days then 28 C thereafter)
decreased the yield from 17.8 to 15.5 g/l. Interestingly, the
main difference started to obviously appear at days 7 and 8,
where the remaining reducing sugars’ concentration reached
zero from day 6. This may be explained by the observation
of Jin et al.5 during rifamycin B fermentation that the reducing
sugar was still consumed in the stationary phase although the
mycelium growth almost stopped in this phase, which meant
that the consumed sugar was primarily used for rifamycin B
biosynthesis and mycelium maintenance.5. Conclusion
Application of 1.5 vvm aeration rate increased the production
yield. None of the tested pH regimens had a positive impact
on the production. The overall optimization of rifamycin B
production by NCH strain in batch mode in a 6.6 l laboratory
fermentor increased the yield by almost 30% from 13.81 to
17.8 g/l.
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